Tirabrutinib hydrochloride

盐酸泰卢替尼

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameTirabrutinib hydrochloride
Drug Alias NametirabrutinibVelexbruベレキシブルGS-4059ONO-4059
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsCentral Nervous System LymphomaPemphigusChronic Urticaria +[11] 
Global Approved IndicationsLymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2020/03/25
Country/TerritoryUnited StatesTaiwanPoland +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDeciphera Pharmaceuticals IncKyorin UniversityDeciphera Pharmaceuticals Llc +[4] 
Inactive CompaniesGilead Sciences Inc
Active IndicationsCentral Nervous System LymphomaPemphigusWaldenstrom Macroglobulinemia +[5] 
Inactive IndicationsChronic UrticariaSjogren's SyndromeArthritis, Rheumatoid +[6] 

Other Information

ATC CodeL01XE
Related LinksDrugBankKEGG